Raab & Moskowitz Asset Management LLC Buys 1,148 Shares of Merck & Co., Inc. (NYSE:MRK)

Raab & Moskowitz Asset Management LLC raised its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 2.5% in the 1st quarter, HoldingsChannel reports. The firm owned 47,640 shares of the company’s stock after purchasing an additional 1,148 shares during the period. Merck & Co., Inc. makes up 1.4% of Raab & Moskowitz Asset Management LLC’s portfolio, making the stock its 18th biggest position. Raab & Moskowitz Asset Management LLC’s holdings in Merck & Co., Inc. were worth $3,672,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Norges Bank bought a new stake in shares of Merck & Co., Inc. in the 4th quarter worth approximately $2,250,767,000. Nuveen Asset Management LLC increased its position in Merck & Co., Inc. by 20.4% during the 4th quarter. Nuveen Asset Management LLC now owns 24,251,965 shares of the company’s stock valued at $1,983,811,000 after purchasing an additional 4,112,158 shares during the period. Morgan Stanley increased its position in Merck & Co., Inc. by 16.7% during the 4th quarter. Morgan Stanley now owns 22,569,366 shares of the company’s stock valued at $1,846,174,000 after purchasing an additional 3,221,509 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Merck & Co., Inc. by 0.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 18,956,192 shares of the company’s stock worth $1,550,617,000 after buying an additional 139,485 shares during the period. Finally, California Public Employees Retirement System grew its position in shares of Merck & Co., Inc. by 31.6% in the 4th quarter. California Public Employees Retirement System now owns 13,542,412 shares of the company’s stock worth $1,107,769,000 after buying an additional 3,252,367 shares during the period. Hedge funds and other institutional investors own 72.86% of the company’s stock.

Shares of MRK stock traded up $0.16 on Tuesday, hitting $76.14. The stock had a trading volume of 207,340 shares, compared to its average volume of 11,885,203. The company has a quick ratio of 1.00, a current ratio of 1.30 and a debt-to-equity ratio of 0.90. The business has a 50 day moving average price of $76.83 and a 200 day moving average price of $78.38. The company has a market cap of $192.66 billion, a PE ratio of 16.81, a P/E/G ratio of 1.89 and a beta of 0.43. Merck & Co., Inc. has a one year low of $71.71 and a one year high of $87.80.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Thursday, April 29th. The company reported $1.40 earnings per share for the quarter, missing the consensus estimate of $1.63 by ($0.23). The firm had revenue of $12.08 billion during the quarter, compared to the consensus estimate of $12.71 billion. Merck & Co., Inc. had a net margin of 24.33% and a return on equity of 53.83%. The business’s revenue was up .2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.50 earnings per share. Equities research analysts expect that Merck & Co., Inc. will post 5.9 EPS for the current year.

Several research firms have issued reports on MRK. Cantor Fitzgerald restated an “overweight” rating on shares of Merck & Co., Inc. in a research note on Friday, February 5th. SVB Leerink cut their target price on shares of Merck & Co., Inc. from $103.00 to $102.00 and set an “outperform” rating for the company in a report on Friday. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $97.22.

Merck & Co., Inc. Company Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products.

Read More: What is a trade deficit?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.